Study Evaluating the Prevalence of Undiagnosed Psoriatic Arthritis in Patients With Plaque Psoriasis
Not Applicable
Recruiting
- Conditions
- Plaque psoriasisPsoriatic arthritisSkin - Dermatological conditionsMusculoskeletal - Other muscular and skeletal disorders
- Registration Number
- ACTRN12610000272099
- Lead Sponsor
- Wyeth Australia Pty Limited
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 500
Inclusion Criteria
1. Diagnosis of plaque psoriasis
2. >= 18 years of age
3. Able to complete English-language questionnaires
Exclusion Criteria
1. Participation in an interventional clinical trial in previous 3 months
2. Known rheumatologist-confirmed psoriatic arthritis
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Prevalence of undiagnosed psoriatic arthritis in patients presenting with plaque psoriasis[This will be measured at the end of the study.]
- Secondary Outcome Measures
Name Time Method Evaluate the relationship between the Psoriatic Arthritis Screening and Evaluation (PASE) score and rheumatologist-confirmed diagnosis of psoriatic arthritis (PsA)[This will be measured at the end of the study.]
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link plaque psoriasis to undiagnosed psoriatic arthritis in ACTRN12610000272099?
How does psoriatic arthritis prevalence in plaque psoriasis patients compare to standard-of-care diagnostic rates in dermatology?
What biomarkers correlate with disease severity and quality of life in psoriatic arthritis patients with plaque psoriasis?
What adverse events are associated with early psoriatic arthritis detection in plaque psoriasis populations?
How do IL-23 inhibitors compare to disease-modifying antirheumatic drugs in managing psoriatic arthritis comorbidities?